The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients

Felicia Pant, Carla Giordano, Maria Pia Amato, Alberto Pugliese, Maria Donatelli, Giuseppa D'Acquisito, Aldo Galluzzo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In autoimmune disease the functional deficiency of T suppressor cells, also described in Type I diabetes, may be restored through immunoglobulin (Ig) infusion, which increases antigen phagocytosis, NK activity, cell clones and antibody anti-idiotype responses. Sixteen Type I diabetic patients were studied: eight were treated soon after the initial correction of disease-onset glycemic deterioration with intensive intravenous (i.v.) 7S Ig treatment (0.4 g/kg/BW) for 1 week and once per week for 6 months, whilst the remaining patients constituted the control group. All patients were evaluated during the study for metabolic and immunological parameters. A reduction in insulin requirement compared to conventionally treated patients was observed at the third (0.17±0.06 vs 0.44±0.08 IU/kg/BW; P<0.02) and at the sixth month of therapy (0.19±0.07 vs 0.54±0.07 IU/kg/BW; P<0.005). Two patients ceased to require insulin therapy within the first month, showing a prolonged restoration of B-cell function. Serum C-peptide values were also significantly higher in the Ig-treated group compared to the control group after 3 and 6 months. As regards immunological parameters, patients showed a decrease in insulin antibody levels and a reduction in TAC+ cells. Intravenous Ig therapy seems able to affect positively the first phases of metabolic and immunological deterioration of Type I diabetes.

Original languageEnglish
Pages (from-to)587-592
Number of pages6
JournalJournal of Autoimmunity
Volume3
Issue number5
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Intravenous Immunoglobulins
Type 1 Diabetes Mellitus
Immunoglobulins
Insulin
Insulin Antibodies
Control Groups
Passive Immunization
C-Peptide
Phagocytosis
Natural Killer Cells
Autoimmune Diseases
Anti-Idiotypic Antibodies
B-Lymphocytes
Therapeutics
Clone Cells
Antigens
Serum

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. / Pant, Felicia; Giordano, Carla; Amato, Maria Pia; Pugliese, Alberto; Donatelli, Maria; D'Acquisito, Giuseppa; Galluzzo, Aldo.

In: Journal of Autoimmunity, Vol. 3, No. 5, 01.01.1990, p. 587-592.

Research output: Contribution to journalArticle

Pant, Felicia ; Giordano, Carla ; Amato, Maria Pia ; Pugliese, Alberto ; Donatelli, Maria ; D'Acquisito, Giuseppa ; Galluzzo, Aldo. / The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. In: Journal of Autoimmunity. 1990 ; Vol. 3, No. 5. pp. 587-592.
@article{0bbd9318ded04659bb58a7c10b2046ac,
title = "The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients",
abstract = "In autoimmune disease the functional deficiency of T suppressor cells, also described in Type I diabetes, may be restored through immunoglobulin (Ig) infusion, which increases antigen phagocytosis, NK activity, cell clones and antibody anti-idiotype responses. Sixteen Type I diabetic patients were studied: eight were treated soon after the initial correction of disease-onset glycemic deterioration with intensive intravenous (i.v.) 7S Ig treatment (0.4 g/kg/BW) for 1 week and once per week for 6 months, whilst the remaining patients constituted the control group. All patients were evaluated during the study for metabolic and immunological parameters. A reduction in insulin requirement compared to conventionally treated patients was observed at the third (0.17±0.06 vs 0.44±0.08 IU/kg/BW; P<0.02) and at the sixth month of therapy (0.19±0.07 vs 0.54±0.07 IU/kg/BW; P<0.005). Two patients ceased to require insulin therapy within the first month, showing a prolonged restoration of B-cell function. Serum C-peptide values were also significantly higher in the Ig-treated group compared to the control group after 3 and 6 months. As regards immunological parameters, patients showed a decrease in insulin antibody levels and a reduction in TAC+ cells. Intravenous Ig therapy seems able to affect positively the first phases of metabolic and immunological deterioration of Type I diabetes.",
author = "Felicia Pant and Carla Giordano and Amato, {Maria Pia} and Alberto Pugliese and Maria Donatelli and Giuseppa D'Acquisito and Aldo Galluzzo",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/S0896-8411(05)80025-3",
language = "English",
volume = "3",
pages = "587--592",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients

AU - Pant, Felicia

AU - Giordano, Carla

AU - Amato, Maria Pia

AU - Pugliese, Alberto

AU - Donatelli, Maria

AU - D'Acquisito, Giuseppa

AU - Galluzzo, Aldo

PY - 1990/1/1

Y1 - 1990/1/1

N2 - In autoimmune disease the functional deficiency of T suppressor cells, also described in Type I diabetes, may be restored through immunoglobulin (Ig) infusion, which increases antigen phagocytosis, NK activity, cell clones and antibody anti-idiotype responses. Sixteen Type I diabetic patients were studied: eight were treated soon after the initial correction of disease-onset glycemic deterioration with intensive intravenous (i.v.) 7S Ig treatment (0.4 g/kg/BW) for 1 week and once per week for 6 months, whilst the remaining patients constituted the control group. All patients were evaluated during the study for metabolic and immunological parameters. A reduction in insulin requirement compared to conventionally treated patients was observed at the third (0.17±0.06 vs 0.44±0.08 IU/kg/BW; P<0.02) and at the sixth month of therapy (0.19±0.07 vs 0.54±0.07 IU/kg/BW; P<0.005). Two patients ceased to require insulin therapy within the first month, showing a prolonged restoration of B-cell function. Serum C-peptide values were also significantly higher in the Ig-treated group compared to the control group after 3 and 6 months. As regards immunological parameters, patients showed a decrease in insulin antibody levels and a reduction in TAC+ cells. Intravenous Ig therapy seems able to affect positively the first phases of metabolic and immunological deterioration of Type I diabetes.

AB - In autoimmune disease the functional deficiency of T suppressor cells, also described in Type I diabetes, may be restored through immunoglobulin (Ig) infusion, which increases antigen phagocytosis, NK activity, cell clones and antibody anti-idiotype responses. Sixteen Type I diabetic patients were studied: eight were treated soon after the initial correction of disease-onset glycemic deterioration with intensive intravenous (i.v.) 7S Ig treatment (0.4 g/kg/BW) for 1 week and once per week for 6 months, whilst the remaining patients constituted the control group. All patients were evaluated during the study for metabolic and immunological parameters. A reduction in insulin requirement compared to conventionally treated patients was observed at the third (0.17±0.06 vs 0.44±0.08 IU/kg/BW; P<0.02) and at the sixth month of therapy (0.19±0.07 vs 0.54±0.07 IU/kg/BW; P<0.005). Two patients ceased to require insulin therapy within the first month, showing a prolonged restoration of B-cell function. Serum C-peptide values were also significantly higher in the Ig-treated group compared to the control group after 3 and 6 months. As regards immunological parameters, patients showed a decrease in insulin antibody levels and a reduction in TAC+ cells. Intravenous Ig therapy seems able to affect positively the first phases of metabolic and immunological deterioration of Type I diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0025039115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025039115&partnerID=8YFLogxK

U2 - 10.1016/S0896-8411(05)80025-3

DO - 10.1016/S0896-8411(05)80025-3

M3 - Article

C2 - 2252526

AN - SCOPUS:0025039115

VL - 3

SP - 587

EP - 592

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 5

ER -